Skip to main content
Erschienen in: Journal of Neuro-Oncology 3/2007

01.07.2007 | Laboratory Investigation

Expression of VEGF and its receptor genes in intracranial schwannomas

verfasst von: Toshio Uesaka, Tadahisa Shono, Satoshi O. Suzuki, Akira Nakamizo, Hiroaki Niiro, Masahiro Mizoguchi, Toru Iwaki, Tomio Sasaki

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Vascular endothelial growth factor (VEGF) is considered to be a major regulator of angiogenesis in various brain tumors. In this study, we determined the expression levels of VEGF, and vascular endothelial growth factor receptor (VEGFR)-1 and -2 mRNA in 46 intracranial schwannomas by quantitative real-time PCR, and correlated these with various clinical factors or other molecular markers. We found that these tumors expressed significant amounts of VEGF mRNA in comparison with other brain tumors, including malignant gliomas and meningiomas. In addition, we performed immunohistochemical studies for VEGF and VEGFR-1, and confirmed that these tumors prominently express these proteins. The expression levels of VEGF and VEGFR-1 mRNA in recurrent tumors were higher than those in primary tumors. When we divided patients into two groups according to VEGF mRNA expression in the tumor, there was no significant difference in patient age, gender, or cranial nerves of origin between groups; however, the tumor volume tended to be larger in the high VEGF group than in the low VEGF group. The levels of VEGFR-1 mRNA and neurofibromatosis-2 mRNA in the high VEGF group were significantly greater than those in the low VEGF group. Levels of VEGFR-2 mRNA and DNA topoisomerase IIα mRNA, and the MIB-1 labeling index in the high VEGF group were slightly higher than those in the low VEGF group; however, the difference was not statistically significant. Based on these observations, the significance of VEGF and its receptor genes in intracranial schwannomas is discussed.
Literatur
1.
Zurück zum Zitat Woodruff JM, Kourea HP, Louis DN, Scheithauer BW (2000) Schwannoma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumors of the nervous system. International Agency for Reseach on Cancer Press, Lyon, pp 164–166 Woodruff JM, Kourea HP, Louis DN, Scheithauer BW (2000) Schwannoma. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of tumors of the nervous system. International Agency for Reseach on Cancer Press, Lyon, pp 164–166
2.
Zurück zum Zitat Herwadker A, Vokurka EA, Evans DG, Ramsden RT, Jackson A (2005) Size and growth rate of sporadic vestibular schwannoma: predictive value of information available at presentation. Otol Neurotol 26:86–92PubMedCrossRef Herwadker A, Vokurka EA, Evans DG, Ramsden RT, Jackson A (2005) Size and growth rate of sporadic vestibular schwannoma: predictive value of information available at presentation. Otol Neurotol 26:86–92PubMedCrossRef
3.
Zurück zum Zitat Nakasu S, Nakasu Y, Nakajima M, Yokoyama M, Matsuda M, Handa J (1996) Potential doubling time and tumour doubling time in meningiomas and neurinomas. Acta Neurochir (Wien) 138:763–770CrossRef Nakasu S, Nakasu Y, Nakajima M, Yokoyama M, Matsuda M, Handa J (1996) Potential doubling time and tumour doubling time in meningiomas and neurinomas. Acta Neurochir (Wien) 138:763–770CrossRef
4.
Zurück zum Zitat Abe M, Kawase T, Urano M, Mizoguchi Y, Kuroda M, Kasahara M, Suzuki H, Kanno T (2000) Analyses of proliferative potential in schwannomas. Brain Tumor Pathol 17:35–40PubMedCrossRef Abe M, Kawase T, Urano M, Mizoguchi Y, Kuroda M, Kasahara M, Suzuki H, Kanno T (2000) Analyses of proliferative potential in schwannomas. Brain Tumor Pathol 17:35–40PubMedCrossRef
5.
Zurück zum Zitat Welling DB, Lasak JM, Akhmametyeva E, Ghaheri B, Chang LS (2002) cDNA microarray analysis of vestibular schwannomas. Otol Neurotol 23:736–748PubMedCrossRef Welling DB, Lasak JM, Akhmametyeva E, Ghaheri B, Chang LS (2002) cDNA microarray analysis of vestibular schwannomas. Otol Neurotol 23:736–748PubMedCrossRef
6.
Zurück zum Zitat Saito K, Kato M, Susaki N, Nagatani T, Nagasaka T, Yoshida J (2003) Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas. Clin Neuropathol 22:30–34PubMed Saito K, Kato M, Susaki N, Nagatani T, Nagasaka T, Yoshida J (2003) Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas. Clin Neuropathol 22:30–34PubMed
7.
Zurück zum Zitat Caye-Thomasen P, Werther K, Nalla A, Bog-Hansen TC, Nielsen HJ, Stangerup SE, Thomsen J (2005) VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 26:98–101PubMedCrossRef Caye-Thomasen P, Werther K, Nalla A, Bog-Hansen TC, Nielsen HJ, Stangerup SE, Thomsen J (2005) VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 26:98–101PubMedCrossRef
8.
Zurück zum Zitat Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676PubMedCrossRef Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676PubMedCrossRef
9.
Zurück zum Zitat Schratzberger P, Schratzberger G, Silver M, Curry C, Kearney M, Magner M, Alroy J, Adelman LS, Weinberg DH, Ropper AH, Isner JM (2000) Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med 6:405–413PubMedCrossRef Schratzberger P, Schratzberger G, Silver M, Curry C, Kearney M, Magner M, Alroy J, Adelman LS, Weinberg DH, Ropper AH, Isner JM (2000) Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med 6:405–413PubMedCrossRef
10.
Zurück zum Zitat Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M, Fukui M (1995) Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 55:1189–1193PubMed Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M, Fukui M (1995) Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 55:1189–1193PubMed
11.
Zurück zum Zitat Nishikawa R, Cheng SY, Nagashima R, Huang HJ, Cavenee WK, Matsutani M (1998) Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathol (Berl) 96:453–462CrossRef Nishikawa R, Cheng SY, Nagashima R, Huang HJ, Cavenee WK, Matsutani M (1998) Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathol (Berl) 96:453–462CrossRef
12.
Zurück zum Zitat Caye-Thomasen P, Baandrup L, Jacobsen GK, Thomsen J, Stangerup SE (2003) Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope 113:2129–2134PubMedCrossRef Caye-Thomasen P, Baandrup L, Jacobsen GK, Thomsen J, Stangerup SE (2003) Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope 113:2129–2134PubMedCrossRef
13.
Zurück zum Zitat Huang H, Held-Feindt J, Buhl R, Mehdorn HM, Mentlein R (2005) Expression of VEGF and its receptors in different brain tumors. Neurol Res 27:371–377PubMedCrossRef Huang H, Held-Feindt J, Buhl R, Mehdorn HM, Mentlein R (2005) Expression of VEGF and its receptors in different brain tumors. Neurol Res 27:371–377PubMedCrossRef
14.
Zurück zum Zitat Parliament MB, Allalunis-Turner MJ, Franko AJ, Olive PL, Mandyam R, Santos C, Wolokoff B (2000) Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours. Br J Cancer 82:635–641PubMedCrossRef Parliament MB, Allalunis-Turner MJ, Franko AJ, Olive PL, Mandyam R, Santos C, Wolokoff B (2000) Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours. Br J Cancer 82:635–641PubMedCrossRef
15.
Zurück zum Zitat Stefanik DF, Fellows WK, Rizkalla LR, Rizkalla WM, Stefanik PP, Deleo AB, Welch WC (2001) Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor; FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol 55:91–100PubMedCrossRef Stefanik DF, Fellows WK, Rizkalla LR, Rizkalla WM, Stefanik PP, Deleo AB, Welch WC (2001) Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor; FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol 55:91–100PubMedCrossRef
16.
Zurück zum Zitat Brieger J, Bedavanija A, Lehr HA, Maurer J, Mann WJ (2003) Expression of angiogenic growth factors in acoustic neurinoma. Acta Otolaryngol 123:1040–1045PubMedCrossRef Brieger J, Bedavanija A, Lehr HA, Maurer J, Mann WJ (2003) Expression of angiogenic growth factors in acoustic neurinoma. Acta Otolaryngol 123:1040–1045PubMedCrossRef
17.
Zurück zum Zitat Pollock BE, Lunsford LD, Kondziolka D, Sekula R, Subach BR, Foote RL, Flickinger JC (1998) Vestibular schwannoma management. Part II. Failed radiosurgery and the role of delayed microsurgery. J Neurosurg 89:949–955PubMedCrossRef Pollock BE, Lunsford LD, Kondziolka D, Sekula R, Subach BR, Foote RL, Flickinger JC (1998) Vestibular schwannoma management. Part II. Failed radiosurgery and the role of delayed microsurgery. J Neurosurg 89:949–955PubMedCrossRef
18.
Zurück zum Zitat Hanabusa K, Morikawa A, Murata T, Taki W (2001) Acoustic neuroma with malignant transformation. Case report. J Neurosurg 95:518–521PubMedCrossRef Hanabusa K, Morikawa A, Murata T, Taki W (2001) Acoustic neuroma with malignant transformation. Case report. J Neurosurg 95:518–521PubMedCrossRef
19.
Zurück zum Zitat Shin M, Ueki K, Kurita H, Kirino T (2002) Malignant transformation of a vestibular schwannoma after gamma knife radiosurgery. Lancet 360:309–310PubMedCrossRef Shin M, Ueki K, Kurita H, Kirino T (2002) Malignant transformation of a vestibular schwannoma after gamma knife radiosurgery. Lancet 360:309–310PubMedCrossRef
20.
Zurück zum Zitat Hovinga KE, Stalpers LJ, van Bree C, Donker M, Verhoeff JJ, Rodermond HM, Bosch DA, van Furth WR (2005) Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines—a clue to radioresistance? J Neurooncol 74:99–103PubMedCrossRef Hovinga KE, Stalpers LJ, van Bree C, Donker M, Verhoeff JJ, Rodermond HM, Bosch DA, van Furth WR (2005) Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines—a clue to radioresistance? J Neurooncol 74:99–103PubMedCrossRef
Metadaten
Titel
Expression of VEGF and its receptor genes in intracranial schwannomas
verfasst von
Toshio Uesaka
Tadahisa Shono
Satoshi O. Suzuki
Akira Nakamizo
Hiroaki Niiro
Masahiro Mizoguchi
Toru Iwaki
Tomio Sasaki
Publikationsdatum
01.07.2007
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2007
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-007-9336-0

Weitere Artikel der Ausgabe 3/2007

Journal of Neuro-Oncology 3/2007 Zur Ausgabe

Clinical Study–Patient Studies

Atypical papillary glioneuronal tumor

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.